Japanese Encephalitis
A special issue of Tropical Medicine and Infectious Disease (ISSN 2414-6366). This special issue belongs to the section "Vector-Borne Diseases".
Deadline for manuscript submissions: closed (16 June 2023) | Viewed by 938
Special Issue Editor
Special Issue Information
Dear Colleagues,
This Special Issue focuses on the biology of Japanese encephalitis virus (JEV) and the wide range of recent advances in the diagnosis, epidemiology, and control of the infectious disease.
Japanese encephalitis is a viral infection caused by the Japanese encephalitis virus and results in severe acute encephalitis in humans. JEV belongs to the Flaviviridae family and was first isolated from an infected human brain in 1935 in Japan. Japanese encephalitis is widely distributed from the Far East to Southeast and South Asia. In recent years, outbreaks of Japanese encephalitis have been reported in Australia, where Japanese encephalitis had not been reported in the past, indicating the spread of the Japanese encephalitis virus outside of Asia.
In addition, 30,000 to 40,000 cases of Japanese encephalitis are reported annually worldwide, but the epidemic has already been largely prevented in Japan and South Korea due to routine vaccination.
Among the flaviviruses, JEV, West Nile virus, St. Louis encephalitis virus, and Murray Valley encephalitis virus are highly homologous and are called the Japanese encephalitis serotype group (Japanese encephalitis serocomplex). Therefore, there is a risk of cross-reactivity in the diagnosis of JEV infections in regions where these viruses are endemic.
Genotype shift of JEV in Southeast Asian countries and elsewhere has become apparent, and molecular studies are needed to analyze the ecology of JEV, especially the factors that contribute to its spread in infected countries.
An effective vaccine against JEV has been developed and proven to be effective, but other closely related flaviviruses can also protect against infection, and the development of a vaccine that is more effective as a single vaccination is expected.
Prof. Dr. Tomoyoshi Komiya
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Tropical Medicine and Infectious Disease is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- JEV
- vaccines
- epidemiology
- immunology
- treatment
